Our news
Our latest news
Alongside VICARTEM Hôtellerie and Younight Hospitality, EXTENDAM has acquired Hôtel Les Brises, a 50-room 3-star property located on the seafront in La Rochelle.
The hotel will undergo a full repositioning into a boutique hotel: renovation of rooms and common areas, new interior design, air conditioning setting and a new revenue management strategy implementation .
Its location —between the marina, the historic city centre and the La Pallice business district— enables the asset to attract both leisure guests and business travelers.
Inès de l’Aulnoit, Managing Partner at EXTENDAM, explains:
“This acquisition is part of a deep trend in the French hotel market: moving away from standardised properties in favour of more distinctive and personalised experiences.”
This deal is part of a long-term partnership between EXTENDAM and VICARTEM, already behind joint projects in Brussels, Nantes and Paris.
➡️ A transformation helping to diversify the hotel offering on the Atlantic coast.
Winners of the 2025 Green Finance Awards have been announced. Énergie Partagée stands out with two distinctions:
🔹 Winner – “Foundations & Associations”, for its innovative financing offers enabling direct mobilisation of citizen savings to fund locally governed renewable energy projects.
🔹 Winner – “Impact & ESG Investment”, confirming the relevance of citizen financing as a lever for sustainable, transparent and locally rooted investment.
These awards recognise a model that strengthens local energy autonomy while opening up investment to everyone.
➡️ Strong recognition for Énergie Partagée’s financing solutions and their concrete contribution to the energy transition.
Neurodegenerative diseases such as Huntington’s remain incurable, leaving patients and families without treatment or hope.
Dr. Laure Jamot and Professor Frédéric Saudou founded HuntX Pharma in December 2022 to address the root cause: defects in axonal transport, a key mechanism for neuronal communication.
The biotech is developing HX127, a molecule capable of restoring axonal transport—without relying on gene therapy.
👉 Already supported by a €1.7M seed round and winner of the I-Nov competition (France 2030) with an additional €2M, the startup is now preparing its first clinical trials.
🫰 An innovation that could extend beyond Huntington’s disease and open the way to treatments for other neurodegenerative pathologies.